Clinical Results
Aurix is the only therapy of its kind that is FDA-cleared for use on ulcers and wounds of all types. Because of our ongoing commitment to better wound care science, we are always collecting data to refine and improve our technology.
Visible Results in Days, Not Weeks
Demonstrated Clinical Efficacy
HEALING IN WOUNDS >337 DAYS OLD
285 Wounds, 39 Centers, 96.5% response rate in less than 15 days with 2.8 treatments.
90.5% of wounds had a 63.6% volume reduction.
Promotes healing in a wide range of chronic wounds with consistent reduction in area, volume, undermining, sinus tracts and tunneling.
Significantly More Wounds Closed with Aurix
Demonstrated Clinical Efficacy
PROSPECTIVE, RANDOMIZED, CONTROLLED TRIAL IN DIABETIC FOOT ULCERS (DFU)
81% healed in the most common-sized DFUs
Significantly more healing (81.3% vs 42.1%) with Aurix (p = 0.0364)
Mean time to healing = 6 weeks
Featured Study: Sakata
A Retrospective, Longitudinal Study to Evaluate Healing Lower Extremity Wounds
AURIX TREATMENT FOR THREE DIFFERENT WOUNDS
May 4: Prior to Aurix treatment. Wound continued to fail despite two revascularizations.
July 7: Wound bed showing granulation tissue with significant reduction in wound area and volume.
May 26: Wound appearance the day Aurix treatment was initiated, post debridement.
November 4: Full wound closure.
May 4: Prior to Aurix treatment. Wound continued to fail despite two revascularizations.
May 26: Wound appearance the day Aurix treatment was initiated, post debridement.
July 7: Wound bed showing granulation tissue with significant reduction in wound area and volume.
November 4: Full wound closure.
June 25: Diabetic ray amputation site with arteriosclerosis obliterans. Wound not healing despite revascularization.
August 13: Amputation site healing well with granulation tissue visible. Significant reduction in wound area and volume.
July 9: Wound appearance the day Aurix treatment was initiated, pre-debridement.
October 8: Wound after 56 days of Aurix treatment and one week prior to complete healing.
June 25: Diabetic ray amputation site with arteriosclerosis obliterans. Wound not healing despite revascularization.
July 9: Wound appearance the day Aurix treatment was initiated, pre-debridement.
August 13: Amputation site healing well with granulation tissue visible. Significant reduction in wound area and volume.
October 8: Wound after 56 days of Aurix treatment and one week prior to complete healing.
July 22: Prior to Aurix treatment. Diabetic heel ulcer with arteriosclerosis obliterans at initial patient visit.
September 30: Wound healed in 49 days of Aurix treatments.
August 12: Granulation tissue visible in wound bed with significant reduction in wound volume.
July 22: Prior to Aurix treatment. Diabetic heel ulcer with arteriosclerosis obliterans at initial patient visit.
August 12: Granulation tissue visible in wound bed with significant reduction in wound volume.
September 30: Wound healed in 49 days of Aurix treatments.